The latest new contracts, like Clearmind Medicine’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
SciSparc’s Collaboration with Clearmind Medicine Shows MEAI Potential as Novel Weight Loss Drug
Aug 06, 2024•almost 2 years ago
Contract Type
partnership
Tel AvivBiotechnologyHealth Care
Description
SciSparc Ltd. announced a new scientific article showing promising results from a study on MEAI, Clearmind Medicine Inc’s innovative psychoactive molecule, for combating obesity. The collaboration between SciSparc and Clearmind aims to develop innovative proprietary combinations for effective and safe treatments for addictions and for obesity and metabolic syndrome.
Company Information
Company
Clearmind Medicine
Location
Tel Aviv, Tel Aviv District, Israel
About
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.The Company’s intellectual portfolio currently consists of fourteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY.”
Predictive Intelligence
Strategic
ML-powered predictions for Clearmind Medicine's next move
Tel AvivBiotechnologyHealth Care